Modified peptides as therapeutic agents
AssigneeAmgen Inc.
InventorsUlrich Feige, Chuan-Fa Liu, Janet Cheetham, Thomas Boone, Jean Gudas
Life of this patent
Estimating the term…
Loading patent…
AssigneeAmgen Inc.
InventorsUlrich Feige, Chuan-Fa Liu, Janet Cheetham, Thomas Boone, Jean Gudas
Estimating the term…
The present invention concerns fusion of Fc domains with Ang-2 binding peptides and a process for preparing such molecules. In this invention, pharmacologically active compounds are prepared by a process comprising (a) selecting at least one random peptide that binds to Ang-2; and (b) preparing a pharmacologic agent comprising an Fc domain covalently linked to at least one amino acid of the selected peptide. Linkage to the vehicle increases the half-life of the peptide, which otherwise would be quickly degraded in vivo. The preferred vehicle is an Fc domain. The peptide can be selected, for example, by phage display, E. coli display, ribosome display, RNA-peptide screening, yeast-based screening, chemical-peptide screening, rational design, or protein structural analysis.
A composition of matter of formula I
The cell of claim 24, wherein the cell is an E. coli cell.
A process for preparing an Ang-2 binding compound wherein the process comprises:
Dependencies are inferred from the claim text.